<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558413</url>
  </required_header>
  <id_info>
    <org_study_id>BTA585-001</org_study_id>
    <nct_id>NCT02558413</nct_id>
  </id_info>
  <brief_title>Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Single Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biota Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled, double-blind, randomized, single dose escalation Phase 1
      clinical trial to determine the safety and tolerability of BTA-C585 administered orally to
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Day 0 to Day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time 0 to 24 hours</measure>
    <time_frame>0-24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BTA-C585 oral capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 or 100 mg oral capsules; Single ascending doses (SAD) from 50 mg to 800 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTA-C585 matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BTA-C585 Matching placebo capsules; single doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTA-C585 oral capsules</intervention_name>
    <description>BTA-C585; Single ascending doses from 50 mg to 800 mg</description>
    <arm_group_label>BTA-C585 oral capsules</arm_group_label>
    <other_name>BTA585</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTA-C585 matching placebo</intervention_name>
    <description>Single ascending doses to match 50 to 800 mg BTA-C585 capsules</description>
    <arm_group_label>BTA-C585 matching placebo</arm_group_label>
    <other_name>BTA585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women aged 18-60 years;

          -  Weight â‰¥ 50 kg and Body Mass Index (BMI) of 19 to 32;

          -  Female subjects must be of non-childbearing potential;

          -  Male subjects must agree to use a double barrier method of birth control;

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Current or recent (within 14 days of Day 0) bacterial or viral infection;

          -  Positive results for hepatitis B, hepatitis C, or HIV;

          -  Clinically significant abnormalities noted on ECG;

          -  Safety laboratory abnormalities;

          -  Regular use of medications, prescription or non-prescription;

          -  Poor vein access or fear of venipuncture;

          -  Major surgery, significant recent injury or trauma within 30 days;

          -  Received an investigational drug or vaccine within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Novotney-Barry</last_name>
    <role>Study Director</role>
    <affiliation>Biota Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biota Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Viral Diseases</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Paramyxoviridae Infections</keyword>
  <keyword>RSV</keyword>
  <keyword>Respiratory Syncytial Virus</keyword>
  <keyword>Aviragen Therapeutics, Inc.</keyword>
  <keyword>Aviragen Therapeutics</keyword>
  <keyword>Aviragen</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

